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OBJECTIVE—Ingested glucose is detected by specialized sen-
sors in the enteric/hepatoportal vein, which send neural signals
to the brain, which in turn regulates key peripheral tissues.
Hence, impairment in the control of enteric-neural glucose
sensing could contribute to disordered glucose homeostasis. The
aim of this study was to determine the cells in the brain targeted
by the activation of the enteric glucose-sensing system.
RESEARCH DESIGN AND METHODS—We selectively acti-
vated the axis in mice using a low-rate intragastric glucose
infusion in wild-type and glucagon-like peptide-1 (GLP-1) recep-
tor knockout mice, neuropeptide Y– and proopiomelanocortin–
green ﬂuorescent protein–expressing mice, and high-fat diet
diabetic mice. We quantiﬁed the whole-body glucose utilization
rate and the pattern of c-Fos positive in the brain.
RESULTS—Enteric glucose increased muscle glycogen synthe-
sis by 30% and regulates c-Fos expression in the brainstem and
the hypothalamus. Moreover, the synthesis of muscle glycogen
was diminished after central infusion of the GLP-1 receptor
(GLP-1Rc) antagonist Exendin 9-39 and abolished in GLP-1Rc
knockout mice. Gut-glucose–sensitive c-Fos–positive cells of the
arcuate nucleus colocalized with neuropeptide Y–positive neu-
rons but not with proopiomelanocortin-positive neurons. Fur-
thermore, high-fat feeding prevented the enteric activation of
c-Fos expression.
CONCLUSIONS—We conclude that the gut-glucose sensor
modulates peripheral glucose metabolism through a nutrient-
sensitive mechanism, which requires brain GLP-1Rc signaling
and is impaired during diabetes. Diabetes 57:2603–2612, 2008
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lood glucose levels are regulated by a dynamic
interaction between a number of key organ
systems. The gut is the ﬁrst organ involved in
glucose homeostasis because it is the conduit by
which carbohydrate enters the body. Digested carbohy-
drate is transported from the intestinal lumen to the
mesenteric vein, then distributed via the hepatoportal vein
to the liver, and then distributed to the rest of the body. In
the enteric area, which includes intestinal luminal cells
and the mesenteric and hepatoportal veins, glucose is
detected by specialized cells, i.e., enteric glucose sensors.
These sensors transmit signals of endocrine and neuronal
origin to peripheral tissues (1–5). Many of the neuronal
signals are communicated via the vagus nerve to the brain
stem (6,7), which relays the glucose signal to hypotha-
lamic nuclei and then on to pertinent target cells. As an
example, Mithieux et al. (8) reported a novel mechanism
connecting the portal-sensing macronutrient composition
of diet to food intake. This mechanism implies that some
of the energy absorbed by the intestine is transformed into
glucose by gluconeogenesis. Then, specialized cells of the
hepatoportal vein that communicate with the vagus nerve
are able to detect glucose and send a signal toward the
brain for the control of food intake. Nevertheless, the
molecular signals required for the function of the gut-brain
axis are incompletely understood.
The incretin glucagon-like peptide-1 (GLP-1) is a candi-
date regulator of neuronal networks controlling glucose
homeostasis. GLP-1 is secreted by enteroendocrine L cells
and enhances glucose-stimulated insulin secretion (9). Of
direct clinical relevance, both GLP-1 receptor (GLP-1Rc)
agonists (9) and dipeptidyl peptidase IV (DPP-IV) inhibi-
tors are now used to treat type 2 diabetes via potentiation
of GLP-1 action.
Endogenously secreted GLP-1 acts in the hepatic portal
vein to increase the ﬁring rate of the vagus nerve (10,11)
and regulate glucose metabolism (12–14). GLP-1 is also
secreted by neuronal cells from the caudal region of the
brain stem, the nucleus of the tractus solitarius (NTS)
(15,16), and released in various hypothalamic, hippocam-
pal, and cortical nuclei, areas that contain functional
GLP-1Rcs (15,17–22). Hence, GLP-1 is also considered a
neuropeptide, but the control of neural GLP-1 signals in
the regulation of glucose homeostasis is poorly under-
stood. To more precisely understand the signals conveyed
by enteric glucose sensors, we infused glucose into the
mouse stomach at a low rate that resulted in no increase in
circulating glucose levels and therefore allowed for the
activation of enteric, but not systemic or brain, glucose
sensors. We show that under these conditions, whole-body
glucose utilization and muscle glycogen synthesis were
increased, accompanied by increased c-Fos expression in
the brain stem and reduced c-Fos expression in key
hypothalamic nuclei. Furthermore, these actions were
signiﬁcantly diminished in GLP-1Rc knockout mice or
after brain infusion of a GLP-1Rc antagonist. Immunohis-
tochemical studies revealed that the neuronal population
targeted by the enteric glucose signal in the arcuate
nucleus (ARC) of the hypothalamus appears to be com-
posed of neuropeptide Y (NPY)-positive but not proopio-
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DIABETES, VOL. 57, OCTOBER 2008 2603melanocortin (POMC)-positive cells. Finally, these actions
of enteric glucose were reduced in diabetic mice fed a
high-fat, carbohydrate-free diet.
RESEARCH DESIGN AND METHODS
Twelve-week-old C57BL6/J (Janvier, St Berthevin, France), GLP-1Rc knock-
out (in a C57BL6/J background, from our colony), and NPY-green ﬂuorescent
protein (GFP) (in a C57BL6/J background, a gift from J. Friedman) male mice
were housed in a controlled environment (inverted 12-h daylight cycle with
lights off from 10:00 A.M. to 10:00 P.M.) with free access to food and water. Mice
were fed a normal chow (A04; Unite ´ Aliment Rationnel, Villemoisson sur Orge,
France) or a high-fat, carbohydrate-free diet for a period of 4 weeks. The diet
contained 72% fat (corn oil and lard), 28% protein, and 1% carbohydrate, as
energy content. This diet has been shown to induce diabetes before an
increase in body weight (23). All animal experimental procedures were
approved by the Rangueil Hospital Committee of the Rangueil Hospital
(Toulouse, France).
Surgical procedures
Indwelling intragastric catheter. Under anesthesia (ketamine/xylazine,
100 and 10 mg/kg i.p., respectively), a catheter was inserted into the stomach.
Brieﬂy, a 4-mm laparotomy was performed on the left side of the abdomen,
and the stomach was gently extracted. One centimeter of a teﬂon catheter was
inserted into the stomach and secured by surgical glue (Histoacryl; 3M Health
Care, St. Paul, MN). The other extremity of the catheter was tunneled under
the skin and exteriorized at the back of the neck.
Indwelling intracerebroventricular catheter. Under similar anesthesia, a
1-cm midline incision was made across the top of the skull, the animal was
placed on a stereotaxic apparatus, and the periosteum cleaned as described
previously (24). A hole, 1 mm in diameter, was made 0.1 mm lateral, 0.22 mm
anteroposterior from the bregma, and 1.7 mm deep; through it, a cannulae was
inserted to reach the lateral ventricle. Two supporting screws were placed
bilaterally, one in the posterior quadrants of the skull and the other one in the
anterior part of the skull, and secured in place with acrylic dental cement
(Magasin Ge ´ne ´ral Dentaire, Paris, France). The cannulae (Alzet, Lupertino,
CA) was ﬁlled with artiﬁcial cerebral ﬂuid (Harvard Apparatus, Les Ulis,
France) and connected to a sealed Tygon catheter (Norton, Akron, OH). To
determine the role of brain GLP-1 signaling, we infused into the lateral
ventricle of the brain the GLP-1Rc antagonist Exendin 9-39 (Ex9; 0.5 pmol 
kg
1  min
1; Bachem), or artiﬁcial cerebrospinal ﬂuid (Harvard Apparatus) as
control, at a rate of 12 l/h, as previously described (23).
Indwelling intrafemoral catheter. Under similar anesthesia, a catheter
was inserted into the femoral vein as described previously (25).
All mice were allowed to recover for 3 weeks after surgery before
undergoing experimental infusions. The mice that did not regain their
presurgical body weight were not used for subsequent studies.
Training period. Because the nervous system is highly dependent on
perception of environmental stress, 3 weeks after surgery, the mice were
trained for 5 consecutive days with repeated daily handling, before undergo-
ing the ﬁnal experiments (Fig. 1A). Brieﬂy, during the training period, mice
were connected to the infusion system at 9:00 A.M. each morning. While
remaining in their cage bedding, the mice were left untouched inside the cage
in a quiet environment with free access to water. Six hours later, the infusion
pumps were turned on. During the training period, mice were infused daily
with a bolus of water (100 l during 10 min).
On the 3rd day of the training period, the correct catheter implantation was
veriﬁed by infusing a rate of glucose high enough to ensure hyperglycemia (30
mg  kg
1  min
1). The mice were left inside their cage, and glycemia was
followed every 10 min for2hb ygentle sampling of a drop of blood (5 l)
from the tip of the tail vein. Less than 60 l blood was sampled. Mice with a
blood glucose 9 mmol/l after glucose infusion were considered to demon-
strate proper catheter placement and used for further experiments.
Experimental design for the assessment of basal whole-body glucose
turnover rates: protocol 1 (Fig. 1A). The determination of glucose
turnover rate requires that a glucose tracer be infused, reaching a steady-state
concentration into the blood. To respect this principle, a ﬁrst set of mice was
continuously infused with glucose at a rate of 10 mg  kg
1  min
1 or water
into the stomach after6ho ffasting. Simultaneously, a tracer dose of
D-[3-
3H]glucose (Perkin Elmer, Boston, MA) was continuously infused through
the femoral vein at a rate of 10 Ci  kg
1  min
1. Plasma D-[3-
3H]glucose
enrichment was determined from total blood (5 l) collected at the tip of the
tail vein every 10 min of the last hour of infusion. This represents 30 l
blood—hence, a small volume. In previous sets of identical experiments,
hematocrit was assessed before and after the infusion. The values were
similar before (39  1%) and at completion (37  2%) of the infusion, showing
the lack of hemodilution because of the infusion and sampling procedures.
The sampled blood was then immediately deproteinized by a Zn(OH)2
precipitate as previously described (26). After centrifugation, an aliquot of the
supernatant was evaporated to dryness to determine the radioactivity corre-
sponding to D-[3-
3H]glucose. In a second aliquot of the same supernatant,
glucose concentration was assessed by a glucose oxidase method as de-
scribed previously (26).
At completion of the infusion, the liver and hindlimb muscles were quickly
harvested and frozen until assay.
Experimental design to determine c-Fos expression pattern: protocol 2
(Fig. 1A). On the 6th day, to assess neuronal c-Fos expression in mice
without inducing systemic hyperglycemia, animals were infused with a low
rate of glucose (10 mg  kg
1  min
1 for 10 min only) or water into the
stomach (total volume 100 l over 10 min) after6ho ffasting. This rate
represents one-half of the endogenous glucose production over a short period
of time, which allows for the stimulation of the enteric sensor without
inducing systemic hyperglycemia. No handling of the mouse was performed
until the brain was ﬁxed 2 h later as follows. Under anesthesia, a cannulae was
implanted into the left ventricle to ensure the delivery of an ice-cold PBS (0.1
mol/l, pH 7.4) infusion followed by a 4% picric acid buffer and 4% formalde-
hyde infusion. The brain was removed from the skull, postﬁxed with the
formaldehyde buffer, cryoprotected one night in 20% sucrose, sectioned, and
stained for immunohistochemistry.
Immunohistochemistry. Thirty-ﬁve-micrometer–thick slices of frozen brain
coronal sections were used to perform immunohistochemical detection of
c-Fos–expressing cells. Free-ﬂoating brain sections were incubated overnight
with a rabbit polyclonal c-Fos antibody (dilution 1:10,000; Ab-5; Oncogene,
San Diego, CA) at 4°C. Sections were rinsed in PBS and incubated for1ha t
room temperature with a secondary biotinylated goat anti-rabbit antibody
diluted 1:2,000 (The Jackson Laboratories, West Grove, PA). Sections were
incubated for 45 min with a streptavidin-peroxidase complex (The Jackson
Laboratories) at room temperature. After rinsing in PBS, brain sections were
incubated with nickel-peroxidase substrate kit solution (Vector Laboratories,
Orton Southgate, Peterborough, U.K.) at room temperature.
The number of c-Fos–positive cells was determined in the NTS, ARC,
ventromedian hypothalamus (VMH), and dorsomedian hypothalamus (DMN),
quantiﬁed using Visilog 6 software (Neosis, Les Ulis, France), and counted in
one of two counterstained sections separated by 35 m (Fig. 1B).
Colocalization of c-Fos–, NPY-, and POMC-positive cells. Free-ﬂoating
sections at thickness of 35 m in the ARC of the hypothalamus were
processed for the colocalization of c-Fos, NPY, and POMC. In the ﬁrst set of
experiments, POMC and c-Fos were colocalized by immunoﬂuorescence.
After overnight incubation with a rabbit polyclonal anti–c-Fos primary
antibody (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA) at room
temperature, sections were rinsed and incubated for 1 h with biotinylated goat
anti-rabbit IgG (1:200; Jackson ImmunoResearch) and sequentially with
avidin-biotin-horseradish peroxidase for 1 h (1:500; Vector Laboratories).
Signals were ampliﬁed with biotinylated tyramide for 10 min (1:250; Tyramide
Signal Ampliﬁcation; NEN, Boston, MA) before incubation with Cy3-conju-
gated streptavidin antibody (1:200; Jackson ImmunoResearch) for 45 min. For
double labeling with POMC, sections were subsequently incubated with a
rabbit polyclonal anti-POMC primary antibody (1:1,000) overnight at room
temperature and then with Alexa 488-conjugated anti-rabbit antibody (1:100;
Molecular Probes) for 45 min. Each primary antibody was tested separately,
and immunohistochemical controls were performed by omitting the primary
antibody.
In a second set of experiments, NPY and c-Fos were colocalized by
immunohistochemistry because immunoﬂuorescence was not successful.
Brieﬂy, 35-m slices were incubated for 6 h with goat serum (10%) at room
temperature in Tris-buffered saline, pH 7.6. The primary antibody against
c-Fos (1/20,000; Calbiochem) was incubated at room temperature overnight.
The slides were rinsed and treated with H2O2 (1%) for 30 min. The slides were
then incubated with the secondary antibody (1/200) for2ha troom temper-
ature. The secondary antibody was revealed using streptavidin peroxidase
coupled with diaminobenzidine (DAB) nickel staining (Calbiochem). The next
day, a primary antibody against GFP was incubated (1/200; Serotech) with the
slides at room temperature, rinsed, incubated with H2O2 as above, and
incubated with the secondary biotinylated antibody (1/1,000; Jackson Immu-
noResearch) for2ha troom temperature. The slides were rinsed, and the
labeling was revealed using streptavidin peroxidase and DAB-only staining (to
discriminate from c-Fos labeling). NPY- and c-Fos–positive cells were counted
manually by two different experimenters. The percentage of colocalization
was calculated by dividing the number of c-Fos– and NPY–co-positive cells by
the number of NPY-positive cells.
Signals for c-Fos and POMC were captured using a ﬂuorescence micro-
scope (Axioplan 2 Imaging; Carl Zeiss). Colocalization of c-Fos and POMC was
determined by merging the individual signals of c-Fos and POMC with Adobe
Photoshop 7.0 after the number of c-Fos– and POMC-positive cells was
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dividing the number of c-Fos– and POMC–co-positive cells by the number of
POMC-positive cells.
Plasma insulin and GLP-1 (7-36) concentrations. In a fourth set of
experiments to determine portal plasma parameters, portal blood was col-
lected just after completion of the 10-min intragastric injection in tubes
containing 10 l/ml DPP-IV inhibitor (Linco Research, St. Charles, MO). At
completion of the infusions, the mice were rapidly anesthetized with ket-
amine/xylazine, the portal vein was surgically exposed, and a sample of portal
blood (200 l) was collected. Plasma was immediately sampled and frozen for
further analyses.
Plasma biochemical analyses. Portal plasma glucose concentration was
measured using an enzymatic glucose oxidase procedure (Elitech Sopachem,
Wageningen, The Netherlands). Portal and systemic plasma insulin levels
were measured by ELISA (Ultrasensitive Mouse Insulin-High Range Mouse
Insulin ELISA kit; Mercodia, Uppsala, Sweden). Portal plasma GLP-1 (7-36)
amide concentrations were measured using an ELISA method (GLP-1 active
ELISA kit; Linco Research) as previously described (27).
Determinations of liver and muscle glycogen synthesis rates. Liver and
muscle glycogen synthesis rates were determined by extracting total glyco-
gen, which includes unlabeled glycogen and [3-
3H]glycogen, with 6% (w/v)
perchloric acid and precipitating glycogen with ethanol as previously de-
scribed (24). Brieﬂy, 100 mg hindlimb muscle or liver were homogenized in 10
volumes of perchloric acid and spun down to eliminate nonhomogenized
particles. The supernatant was precipitated with 15 volumes of ice-cold
absolute ethanol overnight. The glycogen was precipitated by an overnight
exposure at 20°C and recovered by centrifugation. The precipitating proce-
dure was performed twice to ensure the elimination of soluble D-[3-
3H]glu-
cose. The precipitated radioactive glycogen was then dissolved in distilled
water, and the radioactivity was counted in the presence of scintillation buffer.
Calculations and statistical analysis. Calculation of glucose turnover was
made from parameters obtained during the last 60 min of the infusions under
steady-state conditions as described previously (24). Brieﬂy, the D-[3-
3H]glu-
cose speciﬁc activity was calculated by dividing the D-[3-
3H]glucose enrich-
ment by the plasma glucose concentration. The whole-body glucose turnover
rate was calculated by dividing the rate of D-[3-
3H]glucose infusion by the
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FIG. 1. A: Experimental design to analyze the effect of an intragastric glucose infusion. Mice bearing intragastric, femoral, and intracerebro-
ventricular catheters underwent infusions after the surgery recovery period. On days 1, 2, 4, and 5 of the training period, mice were trained to
the intragastric water infusion. On day 3, an intragastric glucose infusion (30 mg  kg
1  min
1) was performed, and those mice developing
immediate hyperglycemia demonstrated a correct intragastric catheter implantation and were studied on day 6 when they underwent an
intragastric glucose or water infusion after6ho ffasting. Two protocols were set up. In protocol 1, glucose turnover was assessed and the mice
underwent a continuous intragastric glucose infusion for 2 h. In protocol 2, the mice underwent a 10-min intragastric glucose or water infusion,
and 2 h later, the brain was ﬁxed in vivo for histological studies. B: Schematic representation in gray of brain areas analyzed to quantify the
number of c-Fos–positive cells (37). C: Glycemic proﬁles (mmol/l) in mice infused with glucose (f) or saline (). The inset represents the
corresponding AUC (arbitrary units). No differences were noticed.
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3H]glucose plasma speciﬁc activity. Endogenous glucose production rate
cannot be calculated because our experimental procedure does not allow the
determination of the enteric glucose absorption or net hepatic glucose uptake
rates. Since the unlabeled glucose is not infused into the same compartment
as the tritiated glucose, the turnover rate cannot take into account the rate of
hepatic glucose production. Consequently, the whole-body glucose utilization
rate cannot be the sum of endogenous glucose production and exogenous
glucose infusion rates. Similar reasoning and calculations were discussed
previously (4,14,28).
The whole-body glycolytic ﬂux was calculated from the [
3H]2O accumu-
lated in the plasma during the last hour of the infusions. The whole-body
glycogen synthesis rate was calculated by subtracting the glycolytic ﬂux from
the glucose turnover rate. For each mouse, the mean values have been
calculated and then averaged with values from mice from the same group. The
muscle and liver glycogen synthesis rates have been calculated by dividing the
D-[3-
3H]glucose muscle glycogen content by the duration of the infusion and
by the D-[3-
3H]glucose speciﬁc activity in the blood. Hence, the value should
be considered an index of the glycogen synthesis rate. Mice showing varia-
tions of the steady-state D-[3-
3H]glucose speciﬁc activity 15% during this time
period were excluded from the study. Results are presented as means  SE.
Statistical signiﬁcance of differences was analyzed by using Student’s t test for
unpaired bilaterally distributed values of unequal variance. Area under the
curve (AUC) was calculated using the trapezoid rule. Correlations between
parameters were assessed by Pearson’s correlation test using GraphPad Prism
version 4.00 for Windows (GraphPad Software, San Diego, CA; www.graph-
pad.com). Values were considered different when P  0.05.
RESULTS
Effect of intragastric glucose infusion on plasma
parameters. This ﬁrst set of mice was infused with glucose
into the stomach at a rate of one-half of the endogenous
glucose production rate of (10 mg  kg
1  min
1)f o r2h
(Fig. 1A). This experimental procedure selectively acti-
vates the gut-glucose sensor system without producing
systemic hyperglycemia. It could also activate the hepato-
portal glucose sensor, although to a much lower extent,
because the portal glycemia rose modestly from 6.3  0.2
to 7.1  0.3 mmol/l, P  0.05, in water- and glucose-infused
mice, respectively. Similarly, systemic glycemia (tail vein)
was assessed every 5 min for the ﬁrst 20 min and then
every 20 min during the following2hi nthis set of mice
only. Peripheral glycemia varied between 6 and 7 mmol/l
in both water and low glucose infusion rate groups for the
ﬁrst 40 min (Fig. 1C) and then progressively stabilized
between 5 and 6 mmol/l until completion of the infusions.
Consequently, the AUCs of glycemic proﬁles were similar
between glucose- and water-infused mice (Fig. 1C). In
addition, in different sets of animals, the peritoneal
infusion of glucose did not change portal glucose con-
centration (6.61  0.92 vs. 5.91  1.02 mmol/l in saline
and intraperitoneal glucose, respectively). Similarly,
GLP-1 concentration remained unchanged (7.43  0.81
vs. 5.45  0.39 pmol/l in saline and intraperitoneal
glucose, respectively).
These results validate the procedure for predominant
activation of enteric glucose sensors because peripheral
glycemia was only very moderately and transiently in-
creased. This procedure can hence facilitate analysis of
the roles of enteric versus systemic glucose sensors.
In a different set of mice, plasma insulin concentrations
were assessed before and 4 and 15 min after the beginning
of the continuous intragastric glucose infusion procedure.
Systemic plasma insulin concentrations were unchanged
under these conditions: 66  6, 72  6, and 72  30 versus
55  6, 85  18, and 90  30 pmol/l, before and at 4 and
15 min in water- and glucose-infused mice, respectively.
However, portal vein insulin concentration was 264  96
versus 546  72 pmol/l in water- and glucose-infused mice,
respectively. It is noteworthy that despite the increased
portal insulin concentration, no change in systemic insulin
concentration was noticed, suggesting that the liver had a
major role in insulin clearance. Conversely, portal GLP-1
concentrations were unchanged by the enteric glucose
infusion (6.54  0.11 vs. 6.79  0.27 pmol/l in water- and
glucose-infused mice, respectively). To delineate the role
of brain GLP-1 signaling in the control of plasma parame-
ters, Ex9 was infused into the brain, and glucose or water
was infused into the stomach. Portal glucose (6.6  0.6 vs.
6.1  0.5 mmol/l), insulin (106.4  68.3 vs. 98.5  29.8
pmol/l), and GLP-1 (5.6  0.3 vs. 4.4  0.2 pmol/l)
concentrations were similar between mice infused for 10
min with glucose or water into the stomach, respectively.
We performed the same analysis in mice fed a high-fat,
carbohydrate-free diet and showed that portal glucose
(7.2  0.6 vs. 6.2  0.7 mmol/l), insulin (134.3  45.9 vs.
129.8  48.2 pmol/l), and GLP-1 (5.5  0.2 vs. 5.0  0.3
pmol/l) remained unchanged in glucose- and water-infused
mice, respectively. This suggests that the diabetic state has
affected the enteric glucose sensor for the control of
plasma parameters as well.
Effect of intragastric glucose infusion on glucose
turnover rates. To assess the role of the enteric glucose
sensor on the control of glucose fate, a 2-h low-rate
intragastric glucose infusion was performed in conscious,
free-moving mice. Whole-body glucose turnover rate was
elevated by the glucose infusion to 160% of control values
(Fig. 2A). Whole-body glycogen synthesis and glycolytic
rates were increased to the same extent (Fig. 2A). The
increased glucose utilization rate was accompanied by a
twofold augmentation of muscle glycogen synthesis in the
low-rate glucose-infused mice, whereas liver glycogen
synthesis rate was unchanged (Fig. 2B and C). It is
noteworthy that the liver glycogen synthesis rate is very
low in GLP-1Rc knockout mice, which could be due to the
rather hypoinsulinemic state of these mutant mice.
Effect of intragastric glucose infusion on c-Fos ex-
pression pattern in the brain. To determine whether the
effect of the intragastric glucose infusion on the control of
glucose fate was associated with activation of speciﬁc
neuronal populations, we quantiﬁed the number of c-Fos–
positive cells in the NTS, ARC, VMH, and DMN (Fig. 1B)
2 h after an intragastric infusion of water or glucose. In the
NTS, the number of c-Fos–positive cells signiﬁcantly in-
creased by four- to ﬁvefold after glucose infusion. In
contrast, the number of c-Fos–positive cells was reduced
in the ARC, VMH, and DMN hypothalamic nuclei by 75, 30,
and 35%, respectively (Fig. 3A–C).
To assess the putative confounding effects of changes in
osmotic pressure during the intragastric infusion experi-
ment, we studied mice after intragastric infusion with
NaCl (0.9%) (305 vs. 185 mOsmol/l in NaCl and the glucose
solution, respectively). No difference in c-Fos expression
pattern was noted between water- and NaCl-infused mice
(not shown). Hence, because water is considered a natu-
rally ingested solution, all control groups were subse-
quently infused with water. In addition, the procedure
aims at minimizing gastric distension by infusing the
glucose solution for 10 min in a small volume of 100 l.
The same conditions were used in water-infused mice.
Effect of GLP-1Rc blockade on glucose turnover rates
during intragastric glucose infusion. To study the role
of the GLP-1Rc on the control of whole-body glucose
ﬂuxes in response to activation of the gut-glucose sensor,
we infused glucose in the stomach for2hi nGLP-1Rc
knockout mice (protocol 1; Fig. 1A). In these mice, whole-
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rates were no longer increased by gastric glucose infusion
(Fig. 2A). However, the GLP-1Rc knockout mice were not
hyperglycemic. Our experimental design cannot allow for
the precise determination of hepatic glucose production
because glucose was infused into the stomach, and there-
fore no interpretation can be drawn with regard to the role
of the liver. This would require the use of different sets of
tracers not applicable to mouse infusion procedures, as
discussed previously (4).
Because GLP-1Rcs are also present in brain, the elimi-
nation of the enteric glucose signal in GLP-1Rc knockout
mice does not permit precise localization of the speciﬁc
tissues important for the GLP-1Rc–dependent control of
the enteric glucose sensor. To investigate the importance
of brain GLP-1 signaling, we infused the GLP-1Rc antago-
nist Ex9 into the brain of wild-type mice while the glucose
was simultaneously infused into the stomach. Central Ex9
completely eliminated the changes in glucose turnover
rate, glycolysis, and muscle glycogen synthesis, consistent
with ﬁndings using GLP-1Rc knockout mice (Fig. 2A–C).
Hence, GLP-1Rc activation in the brain is necessary for
transduction of the enteric glucose signal.
Effect of GLP-1Rc blockade on c-Fos expression pat-
tern during intragastric glucose infusion. We then
assessed whether activation of the GLP-1Rc was essential
for regulation of the neural c-Fos expression pattern
observed in response to the activation of enteric glucose
sensor. Intragastric glucose infusion failed to increase the
number of c-Fos–positive cells in the NTS of GLP-1Rc
knockout mice (Fig. 4A). Similarly, no effect of enteric
glucose on c-Fos expression was observed in hypotha-
lamic nuclei (Fig. 4B).
Colocalization of c-Fos–positive cells with POMC- or
NPY-positive cells in the ARC. We then identiﬁed the
population of neuronal cells targeted into the brain by the
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FIG. 2. Glucose turnover and glycogen synthesis rates. A: Whole-body
glucose turnover, glycolysis, and glycogen synthesis rates (mg  kg
1 
min
1). Glycogen synthesis rates (pg  mg
1  min
1) in liver (B) and
muscle (C) were assessed after a 2-h water or glucose intragastric
infusion (protocol 1) in wild-type and GLP-1Rc knockout (GLP-1Rc
KO) mice (see protocol 1 in Fig. 1). A subset of wild-type mice was
infused simultaneously with Ex9 into the brain (Ex9). Five to nine
mice per group were studied. *Statistically different from water-
infused control mice when P < 0.05.
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FIG. 3. Pattern of c-Fos–positive cells after an intragastric glucose
infusion. The number of c-Fos–positive cells was quantiﬁed in the NTS
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C57BL/6 mice infused with water () or glucose (f) for 10 min (see
protocol 2 in Fig. 1). C: Representative staining of c-Fos–expressing
cells in each nuclei and condition. Eight mice per group were studied.
*Statistically different from water-infused control mice when P < 0.05.
**Statistically different from water-infused control mice when P < 0.01.
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DIABETES, VOL. 57, OCTOBER 2008 2607enteric glucose signal. Only a relatively small portion (7%)
of all POMC-positive cells was colocalized with c-Fos–
positive cells, and there was no signiﬁcant difference of
number of c-Fos– and POMC–co-positive cells between
water- and glucose-infused mice (Fig. 5A–C). In contrast,
25% of NPY-positive cells expressed c-Fos, and this
proportion decreased to 10% in response to enteric glu-
cose (Fig. 5D–F).
High-fat, carbohydrate-free diet impairs the glucose-
dependent enteric signal. We next assessed the impact
of high-fat, carbohydrate-free diet on c-Fos expression
pattern in the brain in response to enteric glucose.
Fasted glycemia was 7.9  0.6 versus 10.6  0.2 mmol/l
in control mice and mice fed a high-fat, carbohydrate-
free diet, respectively (P  0.05 when comparing both
groups). All mice studied were glucose intolerant as
determined after an intraperitoneal glucose challenge.
The AUCs of the glucose proﬁles were 3,329 and 4,950
mmol  l
1  min
1 in control mice and mice fed a
high-fat, carbohydrate-free diet, respectively (P  0.05
when comparing both groups). We have previously
described the main diabetic features of this animal
model (25). In the diabetic mice, enteric glucose did not
increase whole-body glucose utilization rate (Fig. 6C)o r
modify the c-Fos expression pattern in the NTS or ARC
(Fig. 6A and B).
DISCUSSION
The present study demonstrates the following: 1) the
enteric glucose sensor system controls whole-body glu-
cose utilization, particularly muscle glycogen synthesis; 2)
this sensor results in changes in neuronal activity in both
hypothalamus and brain stem connected to NPY-positive
cells; 3) this sensor requires activation of brain GLP-1Rc;
and 4) the “gut-brain-muscle” axis is altered after high-fat
feeding.
Enteric glucose sensor system controls whole-body
glucose utilization and muscle glycogen synthesis.
During a meal, glucose is absorbed by the intestine and
either stored or oxidized by tissues. In the present study,
we assessed the role of enteric glucose sensors on whole-
body glucose ﬂuxes and glycogen synthesis. To selectively
activate the enteric sensor, glucose was infused into the
stomach at a very low rate that did not induce systemic
hyperglycemia. Under these conditions, whole-body glu-
cose utilization and muscle glycogen synthesis were in-
creased, showing a functional connection between the
enteric area, which includes the portal vein, and peripheral
tissues (Fig. 7). It is noteworthy that although we did not
notice a large increase in the portal glucose concentration
over the ﬁrst 10 min after the glucose administration, we
cannot rule out that the portal sensor was not activated as
well. In favor of a role of intestinal glucose sensing, it has
recently been shown that the sweet-taste receptor subunit
T1R3 and the taste G-protein gustducin are expressed in
enteroendocrine cells and underlie intestinal sugar sensing
and regulation of SGLT1 mRNA and protein (29). We could
hypothesize that this taste receptor would be part of the
enteric glucose sensor. Its activation seems to be mainly
dependent on glucose itself. However, we cannot rule out
that the small rise in portal insulin concentration would
have contributed to the generation of the enteric signal
toward the brain. We previously reported that 2 min after
an oral glucose challenge, there was a rapid increase in
insulin secretion that was dependent on the GLP-1Rc
located into the portal vein (30). However, in the set of
data, the glucose challenge value was much lower than the
classic oral glucose tolerance test. This led to a smaller
increase in portal insulin concentration that was not
reaching the systemic blood.
Our present data suggest that the enteric and brain
sensors generate opposite signals for the control of
peripheral glucose metabolism (Fig. 7). This hypothesis
is supported by previous data demonstrating that glu-
cose infusion directly into the brain, to activate the
corresponding sensor, reduced peripheral glucose utili-
zation (24), whereas in the present study, the activation
of the enteric sensor increases peripheral glucose utili-
zation. Our ﬁndings show that within minutes of admin-
istration into the stomach, glucose can alter neuronal
activity and facilitate peripheral tissues to store glu-
cose. This conclusion is also supported by data from the
literature showing that a low enteric glucose infusion in
the rat rapidly increases pancreatic blood ﬂow, prepar-
ing the islets for insulin secretion through a mechanism
requiring the vagus nerve (31). In addition to the role of the
autonomic nervous system, functional GLP-1Rcs represent
an important component of the enteric glucose sensor.
GLP-1 is released into the portal vein and controls the
ﬁring rate of the vagus nerve (32) and the hepatoportal
sensor system, leading to an increased whole-body glu-
cose utilization rate (14). However, our current data show
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FIG. 4. Pattern of c-Fos–positive cells after an intragastric glucose
infusion in GLP-1Rc knockout mice. The number of c-Fos–expressing
cells was quantiﬁed in the NTS (A) and ARC, VMH, and DMN nuclei (B)
of GLP-1Rc knockout mice (as described in Fig. 1B) infused with water
() or glucose (f). Five mice per group were studied. No differences
were noted between groups.
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remained unchanged 10 min after the initiation of intra-
gastric glucose infusion, hence it is unlikely that portal
GLP-1 represents the gut-glucose signal.
Brain stem and hypothalamic nuclei are differentially
regulated by enteric glucose. The ﬁrst synapse of vagal
afferents are in caudal brain stem nuclei (6), where we
observed increased numbers of c-Fos–expressing cells in
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ingly, the pattern was quite different in hypothalamic
nuclei. Intragastric glucose infusion reduced the number
of c-Fos–expressing cells in the ARC, VMH, and DMN.
Interestingly, data from our group showed that an intra-
gastric glucose infusion high enough to induce systemic
hyperglycemia increased the number of c-Fos–positive
cells in hypothalamic nuclei (unpublished observations).
Similar data were previously reported by others and
showed that a direct glucose infusion in the brain through
the carotid artery increased the number of c-Fos–express-
ing cells in hypothalamic nuclei, notably, the arcuate,
paraventricular, and ventromedian nuclei (33). Together,
the signals generated by the enteric sensor are opposite to
those generated by hyperglycemia in the brain (Fig. 7).
The enteric glucose sensor system sends signals to
peripheral tissues via a mechanism that requires a
functional brain GLP-1Rc. In response to a low-rate
intragastric glucose infusion, the c-Fos expression pattern
in GLP-1Rc knockout mice was different from that de-
tected in wild-type mice. The number of c-Fos–positive
cells was not increased in response to intragastric glucose
in the NTS of GLP-1 Rc knockout mice when compared
with wild-type controls. Similarly, no increased muscle
glycogen synthesis was observed in wild-type mice infused
with glucose into the stomach when the GLP-1Rc antago-
nist Ex9 was simultaneously infused into the brain. This
suggests that GLP-1 could be released in the brain in
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FIG. 6. Pattern of c-Fos–positive cells and glucose utilization rates
after an intragastric glucose infusion in high-fat diet–fed diabetic mice.
The number of c-Fos–expressing cells was quantiﬁed in the NTS (A)
and ARC, VMH, and DMN nuclei (B) of mice fed a high-fat, carbohy-
drate-free diet infused with water () or glucose (f). Five mice per
group were studied. Glucose ﬂux (mg  kg
1  min
1) was studied after
1 week (C) or 1 month (D) of high-fat, carbohydrate-free diet. TO,
turnover; Glycol, glycolysis; and Gln Synth, glycogen synthesis. For all
parameters, no difference was noted between groups.
FIG. 7. Schematic representation of the role of GLP-1 in the brain as a
master switch for the control of glucose fate. 1) Enteric sensors are the
ﬁrst site for glucose detection after an oral glucose load. They send a
neural signal to the NTS. 2) Subsequently, the NTS sends a signal
toward the hypothalamus, including GLP-1. The enteric signal triggers
NPY-positive cells. 3) GLP-1–sensitive cells send a new signal, of
unknown origin, toward peripheral tissues, i.e., muscles, to prepare
cells to use glucose. 4) The brain would detect glucose. 5) Subse-
quently, a signal opposite to the one sent by the enteric glucose
detector would be sent by the brain to the muscle, as previously
described (23). Importantly, the enteric glucose signal is impaired
during diabetes.
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hyperglycemia and hyperinsulinema, the enteric signal
would increase peripheral glucose metabolism (Fig. 7).
Taken together, our current data suggest that enteric
glucose activates a GLP-1Rc–dependent signal in the brain
to control peripheral glucose metabolism. GLP-1–produc-
ing neurons are found largely in the NTS, where they
project to a number of hypothalamic nuclei (15,34), and
therefore may provide a key link between brainstem and
hypothalamic neuronal populations regulated by gastric
glucose infusion.
The enteric glucose signal triggers NPY neurons in
the ARC. We determined that 25% of NPY-positive cells
expressed c-Fos after enteric glucose administration. Im-
portantly, the number of c-Fos/NPY–positive cells, but not
POMC cells, was reduced to 10% in response to intragas-
tric glucose. These data point to a potential role of arcuate
NPY but not POMC cells in regulating enteric glucose
responses. This is consistent with a broad array of evi-
dence that implicates the ARC as an integrator of hor-
monal and nutrient information to regulate both energy
and glucose homeostasis (35,36).
The enteric glucose signal is impaired in high-fat, car-
bohydrate-free diet–induced diabetes. Diabetic mice are
characterized by a state of glucose unresponsiveness. Our
data clearly show that mice maintained on a high-fat,
carbohydrate-free diet had little change in the number of
c-Fos–positive cells in the brain stem in response to
intragastric glucose, and this was paralleled by a failure to
induce changes in glucose utilization rates. Whether these
impairments affect signals arising from the intestine and/or
the brain cannot be determined in our study.
In summary, the available data show that the gut-
glucose sensor sends signals to the brain that control
peripheral glucose utilization in a GLP-1Rc–dependent
manner.
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